Case-control analysis of rs198977 in the KLK2 gene in three studies of prostate cancer
| Nam et al. (11) | CGEMS (27) | CAPS1 | CAPS2 | CAPS1 + CAPS2 | |
|---|---|---|---|---|---|
| Cases, n (%) | |||||
| C/C | 335 (52) | 618 (53) | 788 (56) | 670 (55) | 1,458 (56) |
| C/T | 260 (40) | 472 (40) | 515 (37) | 460 (38) | 975 (37) |
| T/T | 50 (8) | 80 (7) | 94 (7) | 89 (7) | 183 (7) |
| Controls, n (%) | |||||
| C/C | 356 (59) | 630 (57) | 443 (61) | 483 (57) | 926 (59) |
| C/T | 216 (36) | 404 (37) | 233 (32) | 287 (34) | 520 (33) |
| T/T | 34 (6) | 63 (6) | 48 (7) | 72 (9) | 120 (8) |
| P (3 × 2 table) | 0.038 | 0.079 | 0.088 | 0.19 | 0.029 |
| Heterozygote OR (95% CI) | 1.3 (1.0-1.6) | 1.2 (1.0-1.4) | 1.2 (1.0-1.5) | 1.2 (0.96-1.4) | 1.2 (1.0-1.4) |
| Homozygote OR (95% CI) | 1.6 (1.0-2.5) | 1.3 (0.91-1.8) | 1.1 (0.76-1.6) | 0.89 (0.64-1.2) | 1.0 (0.76-1.2) |
| Hardy-Weinberg P (controls) | 0.9 | 0.9 | 0.025 | 0.002 | 0.0001 |
NOTE: Data for the combined cohort of CAPS1 and CAPS2 are included for informational purposes in the last column; these two cohorts were considered separately in the meta-analysis.